Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Hazel Lote"'
Autor:
Hazel Lote, Florentia Mousoullou, George Vlachogiannis, Andrea Lampis, Laura Satchwell, Clare Peckitt, Caroline Fong, Ruwaida Begum, Shannon Kidd, Susan Cromarty, Anderley Gordon, Charlotte Fribbens, Sheela Rao, Naureen Starling, Ian Chau, David Cunningham, Nicola Valeri
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundThis study aimed to identify microRNAs (miRs) as circulating biomarkers of resistance to first-line trastuzumab-based therapy in advanced HER2-positive oesophago-gastric cancer patients.MethodsA high-throughput 1015 Exiqon miRCURY LNA™ mi
Externí odkaz:
https://doaj.org/article/ce00e101c55741ff998c109728418068
Autor:
Francesco Sclafani, Ian Chau, David Cunningham, Jens C. Hahne, George Vlachogiannis, Zakaria Eltahir, Andrea Lampis, Chiara Braconi, Eleftheria Kalaitzaki, David Gonzalez De Castro, Andrew Wotherspoon, Jaume Capdevila, Bengt Glimelius, Noelia Tarazona, Ruwaida Begum, Hazel Lote, Sanna Hulkki Wilson, Giulia Mentrasti, Gina Brown, Diana Tait, Jacqueline Oates, Nicola Valeri
Publikováno v:
Scientific Reports, Vol 8, Iss 1, Pp 1-9 (2018)
Abstract There are limited data on circulating, cell-free, tumour (ct)DNA analysis in locally advanced rectal cancer (LARC). Digital droplet (dd)PCR was used to investigate KRAS/BRAF mutations in ctDNA from baseline blood samples of 97 LARC patients
Externí odkaz:
https://doaj.org/article/2003b11877bd4935942baabe372bee21
Publikováno v:
Case Reports in Oncology, Vol 7, Iss 2, Pp 393-400 (2014)
Poorly differentiated cancers are a diagnostic and therapeutic challenge in oncology. New therapies are needed for patients with poorly differentiated thyroid carcinoma (PDTC) or anaplastic thyroid cancer, as these patients often present with advance
Externí odkaz:
https://doaj.org/article/7ca14aae154249c78f850f6b08437ac6
Autor:
Nicola Valeri, Andrea Sottoriva, Chiara Braconi, Michael Hubank, Jens C. Hahne, Matteo Fassan, Paula Proszek, Thomas Jones, Annette Bryant, Blanka Hezelova, Ruwaida Begum, Massimo Rugge, Nasir Khan, Clare Peckitt, Janet Thomas, Naureen Starling, David Watkins, Gayathri Anandappa, Sheela Rao, Francesco Trevisani, Giulia Mentrasti, Nina Tunariu, Ian Chau, Somaieh Hedayat, Ian Said Huntingford, Hazel Lote, Mahnaz Darvish Damavandi, Andrea Lampis, Alexandra Vatsiou, Javier Fernandez Mateos, Timon Heide, Inmaculada Spiteri, Georgios Vlachogiannis, Benjamin Werner, David Cunningham, Khurum H. Khan
Supplementary Tables
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::396bc62dfb609df54bb332d0e8d774ca
https://doi.org/10.1158/2159-8290.22532239.v1
https://doi.org/10.1158/2159-8290.22532239.v1
Autor:
Nicola Valeri, Andrea Sottoriva, Chiara Braconi, Michael Hubank, Jens C. Hahne, Matteo Fassan, Paula Proszek, Thomas Jones, Annette Bryant, Blanka Hezelova, Ruwaida Begum, Massimo Rugge, Nasir Khan, Clare Peckitt, Janet Thomas, Naureen Starling, David Watkins, Gayathri Anandappa, Sheela Rao, Francesco Trevisani, Giulia Mentrasti, Nina Tunariu, Ian Chau, Somaieh Hedayat, Ian Said Huntingford, Hazel Lote, Mahnaz Darvish Damavandi, Andrea Lampis, Alexandra Vatsiou, Javier Fernandez Mateos, Timon Heide, Inmaculada Spiteri, Georgios Vlachogiannis, Benjamin Werner, David Cunningham, Khurum H. Khan
Supplementary Table S4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::465cd03624778aa0f1c4fbb3557440ab
https://doi.org/10.1158/2159-8290.22532242.v1
https://doi.org/10.1158/2159-8290.22532242.v1
Autor:
Nicola Valeri, Andrea Sottoriva, Chiara Braconi, Michael Hubank, Jens C. Hahne, Matteo Fassan, Paula Proszek, Thomas Jones, Annette Bryant, Blanka Hezelova, Ruwaida Begum, Massimo Rugge, Nasir Khan, Clare Peckitt, Janet Thomas, Naureen Starling, David Watkins, Gayathri Anandappa, Sheela Rao, Francesco Trevisani, Giulia Mentrasti, Nina Tunariu, Ian Chau, Somaieh Hedayat, Ian Said Huntingford, Hazel Lote, Mahnaz Darvish Damavandi, Andrea Lampis, Alexandra Vatsiou, Javier Fernandez Mateos, Timon Heide, Inmaculada Spiteri, Georgios Vlachogiannis, Benjamin Werner, David Cunningham, Khurum H. Khan
Supplementary methods and Figures S1-S17
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bd9d410b0977d6a77198f0a019e304c
https://doi.org/10.1158/2159-8290.22532245.v1
https://doi.org/10.1158/2159-8290.22532245.v1
Autor:
Nicola Valeri, Matteo Fassan, Ian Chau, Jens C. Hahne, Annette Bryant, Isma Rana, Ruwaida Begum, Massimo Rugge, Nicos Fotiadis, Nasir Khan, Ria Kalaitzaki, Clare Peckitt, Janet Thomas, Hazel Lote, Mahnaz Darvish-Damavandi, Chiara Braconi, Naureen Starling, David Watkins, Sheela Rao, Nina Tunariu, Somaieh Hedayat, Georgios Vlachogiannis, Kyriakos Kouvelakis, Khurum H. Khan, David Cunningham, Andrea Lampis, Gayathri Anandappa
Supplementary Figures and Tables
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a888b54255c887f293035659d8f64682
https://doi.org/10.1158/1078-0432.22469264
https://doi.org/10.1158/1078-0432.22469264
Autor:
Nicola Valeri, Matteo Fassan, Ian Chau, Jens C. Hahne, Annette Bryant, Isma Rana, Ruwaida Begum, Massimo Rugge, Nicos Fotiadis, Nasir Khan, Ria Kalaitzaki, Clare Peckitt, Janet Thomas, Hazel Lote, Mahnaz Darvish-Damavandi, Chiara Braconi, Naureen Starling, David Watkins, Sheela Rao, Nina Tunariu, Somaieh Hedayat, Georgios Vlachogiannis, Kyriakos Kouvelakis, Khurum H. Khan, David Cunningham, Andrea Lampis, Gayathri Anandappa
Purpose:Anti-EGFR mAbs are effective in the treatment of metastatic colorectal cancer (mCRC) patients. RAS status and tumor location (sidedness) are predictive markers of patients' response to anti-EGFR mAbs. Recently, low miR-31-3p expression levels
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a74359a64f7c50e315506016814fdc90
https://doi.org/10.1158/1078-0432.c.6527189
https://doi.org/10.1158/1078-0432.c.6527189
Autor:
Hazel Lote, Ian Chau
Publikováno v:
Expert Opinion on Investigational Drugs. 31:59-78
HER2 positive gastric cancer is a distinct subgroup overexpressing the HER2 receptor. For a decade, first-line Trastuzumab was the only licensed HER2-directed therapy for HER2 positive advanced gastric cancer following results from the ToGA trial in
Autor:
Hazel Lote, Florentia Mousoullou, George Vlachogiannis, Caroline Fong, Laura Satchwell, Clare Peckitt, Ruwaida Begum, Shannon Kidd, Susan Cromarty, Anderley Gordon, Charlotte Victoria Fribbens, David J. Watkins, Sheela Rao, Ian Chau, Naureen Starling, David Cunningham, Nicola Valeri
Publikováno v:
Journal of Clinical Oncology. 41:419-419
419 Background: A predictive biomarker for resistance to trastuzumab in HER2 positive oesophago-gastric cancer would refine patient selection. Our preclinical studies suggest that patients with HIGH baseline plasma miR-148a-3p levels will experience